188
Views
11
CrossRef citations to date
0
Altmetric
Original Research

Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan

, , , , &
Pages 205-211 | Published online: 09 Jan 2019

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Peter M. Haddad & Christoph U. Correll. (2023) Long-acting antipsychotics in the treatment of schizophrenia: opportunities and challenges. Expert Opinion on Pharmacotherapy 24:4, pages 473-493.
Read now
Ahmet Kokurcan, Seher Olga Güriz, Hasan Karadağ, Funda Erdi & Sibel Örsel. (2021) Treatment strategies in management of schizophrenia patients with persistent symptoms in daily practice: a retrospective study. International Journal of Psychiatry in Clinical Practice 25:3, pages 238-244.
Read now
Mami Kasahara-Kiritani, Amish Chaturvedi, Ataru Inagaki, Akihide Wakamatsu & Wonjoo Jung. (2020) Budget impact analysis of long acting injection for schizophrenia in Japan. Journal of Medical Economics 23:8, pages 848-855.
Read now

Articles from other publishers (8)

Yiying Sun, Jie Tong, Ying Feng, Haiping Fang, Tao Jiang, Liping Zhao, Qiang Wang & Yi Yang. (2022) Attitude and influencing factors of patients with schizophrenia toward long-acting injections: A community-based cross-sectional investigation in China. Frontiers in Public Health 10.
Crossref
Junli Zhu, Yun Chen, Wei Lu, Qingzhi Huang, Bin Li, Ying Xu, Rui Xi & Lefan Jin. (2021) Attitudes and Willingness to Accept Long-Acting Injections for Patients With Schizophrenia in Beijing: A Cross-Sectional Investigation Based on Samples From the Communities. Frontiers in Public Health 9.
Crossref
John M. Kane, Joseph P. McEvoy, Christoph U. Correll & Pierre-Michel Llorca. (2021) Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia. CNS Drugs 35:11, pages 1189-1205.
Crossref
Lorenzo Tatini, Giulio D’Anna, Francesco Pietrini, Eugenia Calligaris, Andrea Ballerini & Valdo Ricca. (2021) Predictors of long-acting injectable antipsychotic treatment discontinuation in outpatients with schizophrenia: relevance of the Drug Attitude Inventory-10. International Clinical Psychopharmacology 36:4, pages 181-187.
Crossref
Nakao Iwata, Ataru Inagaki, Hiromi Sano, Kazunari Niidome, Yoshitsugu Kojima & Sakiko Yamada. (2020) Treatment Persistence Between Long-Acting Injectable Versus Orally Administered Aripiprazole Among Patients with Schizophrenia in a Real-World Clinical Setting in Japan. Advances in Therapy 37:7, pages 3324-3336.
Crossref
Hiroyuki Kamei, Yuki Homma, Ippei Takeuchi, Genta Hajitsu, Kaori Tozawa, Masakazu Hatano, Aiko Fukui, Manako Hanya, Shigeki Yamada & Nakao Iwata. (2020) Acceptance of the Deltoid Muscle Injection of Aripiprazole Long-acting Injectable in the Patients with Schizophrenia. Clinical Psychopharmacology and Neuroscience 18:1, pages 49-57.
Crossref
Sandeep Grover, Swapnajeet Sahoo & Aseem Mehra. (2019) Perceptions of Psychiatrists Toward the Use of Long-Acting Injectable Antipsychotics. Journal of Clinical Psychopharmacology 39:6, pages 611-619.
Crossref
Sandeep Grover, Swapnajeet Sahoo, Subodh BN, Nidhi Malhotra, Devakshi Dua & Ajit Avasthi. (2019) Attitude and perceptions of patients towards long acting depot injections (LAIs). Asian Journal of Psychiatry 44, pages 200-208.
Crossref